Fight CRC Blog

United to Protect Lifesaving Screenings

As the Supreme Court prepares to hear oral arguments that could reshape the future of no-cost preventive services in the U.S., 38 leading patient advocacy groups and healthcare organizations stand...

Minimal Residual Disease (MRD) Trials

This month we feature clinical trials for colorectal cancer patients with minimal residual disease (MRD) after curative-intent treatment. MRD describes microscopic residual disease, where a very small number of cancer...

What Can I Eat the Day Before a Colonoscopy?

Ever since the dawn of colonoscopy, nearly all patients have been advised to go on a clear liquid diet the day before a procedure and to avoid any solid foods....

GI ASCO Updates

We learned much more about the role of circulating tumor DNA (ctDNA) tests in treating colorectal cancer at this meeting. I’m looking forward to Manju’s insights about that. From my...

Targeted therapy meets immunotherapy: a trial for metastatic KRAS G12C-mutant CRC

In this blog, we take a deep dive into the Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations (NCT06412198) clinical trial...

Fight CRC Names Anjee Davis as CEO, Driving Bold Vision for the Future

Fight Colorectal Cancer (Fight CRC), the nation’s leading advocacy organization for colorectal cancer awareness, research, and policy, is proud to announce the promotion of Anjee Davis to Chief Executive Officer...